{"id":2843,"date":"2024-07-31T13:47:39","date_gmt":"2024-07-31T13:47:39","guid":{"rendered":"https:\/\/raa.ro\/?post_type=publicatie&#038;p=2843"},"modified":"2024-07-31T13:49:04","modified_gmt":"2024-07-31T13:49:04","slug":"glc-monitoring-mission-report-2016","status":"publish","type":"publicatie","link":"https:\/\/raa.ro\/en\/publicatie\/glc-monitoring-mission-report-2016\/","title":{"rendered":"GLC monitoring mission report 2016"},"content":{"rendered":"<p><span style=\"color: #036951;\"><strong>Overview<\/strong><\/span><\/p>\n<p>The rGLC\/Europe supports the implementation and expansion of the M\/XDR-TB Response Plan in Romania. Since the launch of the GFATM project, rGLC has conducted annual monitoring missions, with the latest occurring in March 2015.<\/p>\n<p><span style=\"color: #036951;\"><strong>Key approvals and patient inclusions<\/strong><\/span><\/p>\n<p>Romania received several approvals from GLC for access to quality-assured second-line drugs for a total of 850 MDR-TB patients. Between 2004-2011, a total of 884 MDR-TB patients were included in GLC-approved programs, funded by GFATM grants.<\/p>\n<p><span style=\"color: #036951;\"><strong>Treatment success rates<\/strong><\/span><\/p>\n<ul>\n<li><strong><span style=\"color: #23262a;\">First three cohorts (2004-2005, 2006-2007, 2009):<\/span><\/strong> 364 MDR-TB patients, with an average treatment success rate of 66.8%<\/li>\n<li><strong>2011 cohort:<\/strong> treatment success rate of 73.6%<\/li>\n<\/ul>\n<p>Despite the good performance of GFATM grants related to the TB Program in Romania, the treatment efficacy for non-GLC patient cohorts showed extremely poor results over the years due to various structural, financial, and organizational constraints.<\/p>\n<p><span style=\"color: #036951;\"><strong>Recent developments<\/strong><\/span><\/p>\n<ul>\n<li><strong>Early 2013<\/strong>: GFATM approved TFM funding for a new cohort of 300 patients to be included in 2013-2014. This program started in October 2013 and included treatment regimens for 19 XDR-TB patients.<\/li>\n<li><strong>Future Projections<\/strong>: An additional 1,460 M\/XDR-TB patients will have access to quality-assured second-line drugs and new Group 5 medications, with funding available from the Norwegian Fund and GFATM until March 2018.<\/li>\n<\/ul>\n<p>For more information, you can download the document below.<\/p>\n","protected":false},"author":1,"featured_media":1498,"template":"","meta":{"_acf_changed":false},"cat-publicatie":[71],"tip":[95],"class_list":["post-2843","publicatie","type-publicatie","status-publish","has-post-thumbnail","hentry","cat-publicatie-health","tip-reports"],"acf":[],"_links":{"self":[{"href":"https:\/\/raa.ro\/en\/wp-json\/wp\/v2\/publicatie\/2843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/raa.ro\/en\/wp-json\/wp\/v2\/publicatie"}],"about":[{"href":"https:\/\/raa.ro\/en\/wp-json\/wp\/v2\/types\/publicatie"}],"author":[{"embeddable":true,"href":"https:\/\/raa.ro\/en\/wp-json\/wp\/v2\/users\/1"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/raa.ro\/en\/wp-json\/wp\/v2\/media\/1498"}],"wp:attachment":[{"href":"https:\/\/raa.ro\/en\/wp-json\/wp\/v2\/media?parent=2843"}],"wp:term":[{"taxonomy":"cat-publicatie","embeddable":true,"href":"https:\/\/raa.ro\/en\/wp-json\/wp\/v2\/cat-publicatie?post=2843"},{"taxonomy":"tip","embeddable":true,"href":"https:\/\/raa.ro\/en\/wp-json\/wp\/v2\/tip?post=2843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}